2026-10-15T07:26:46Z https://data.mendeley.com/oai

oai:data.mendeley.com/75xwz2849j.1 2024-04-04T09:52:29Z

Dubost-Brama, Ariane Supplement - Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2) Mendeley Data Supplement - Contents: Plain Language Summary Table SI. Comorbid conditions present in the medical history of 5% or more of the trial population Table SII. Medical history of psychiatric comorbidities in the trial population Table SIII. Use of concomitant prohibited medications/procedures and/or rescue medication Fig S1. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Study design Fig S2. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Patient disposition Fig S3. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Baseline demographic characteristic subgroup analyses of responders at week 24 Fig S4. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Proportion of patients achieving ≥4-point reduction in WI-NRS from baseline over time Fig S5. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Efficacy on patient-reported outcomes mean change from baseline to week 24 Skin Lesion Pruritus Yosipovitch, Gil Kim, Brian S. Kwatra, Shawn Mollanazar, Nicholas K. Satoh, Takahiro Staender, Sonja Mendes-Bastos, Pedro Tsai, Tsen-Fang Laws, Elizabeth Nivens, Michael C. Maloney, Jennifer Shi, Genming Bansal, Ashish Dataset doi:10.17632/75xwz2849j.1 oai:data.mendeley.com/75xwz2849j.1 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/75xwz2849j 2024-04-04T09:52:29Z